PUGE: U.S. #$%$ market will quadruple next five years.
GWP decade ahead of competitors THC and cannaboid delivery method. $62 target is conservative.
There is no US approved drug to treat PTSD. Cannoboid may be the cure.
OTC: PUGE Cannabis BioTech is investigating alternatives such as topical applications and infusing active ingredients into foods and beverages, which will open up the benefits to a significantly larger segment of the population. The company is also exploring sophisticated transmucosal delivery systems (administered through the mucous membranes).
According to a recent Pew Research report, for the first time in more than 40 years a majority of Americans favor legalization of marijuana use. The manner in which it is consumed is producing a fast-growing industry in alternative delivery methods. The Wall Street Journal reported the $1.7 billion U.S. #$%$ market will quadruple in size during the next five years.
PROFIT: Projected cannabis sales are $3 billion in 2014 and $6 billion in 2016. In US 20 states plus the District of Columbia have legalized cannabis for medical reasons and the list of states will continue to grow.